Spots Global Cancer Trial Database for icc
Every month we try and update this database with for icc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma | NCT02415036 | Hepatocellular ... Intrahepatic Ch... | Delcath Hepatic... Melphalan | 18 Years - | Delcath Systems Inc. | |
| Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC | NCT04682249 | ICC | Systemic Chemot... Sintilimab Apatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway | NCT01917370 | Intrahepatic Ch... | surgical treatm... | 16 Years - 90 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway | NCT01917370 | Intrahepatic Ch... | surgical treatm... | 16 Years - 90 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC | NCT04682249 | ICC | Systemic Chemot... Sintilimab Apatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma | NCT02415036 | Hepatocellular ... Intrahepatic Ch... | Delcath Hepatic... Melphalan | 18 Years - | Delcath Systems Inc. | |
| Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | NCT05220722 | Hepatocellular ... Intrahepatic Ch... | SD-101 Pembrolizumab Nivolumab Ipilimumab | 18 Years - 99 Years | TriSalus Life Sciences, Inc. | |
| Systemic Chemotherapy Plus PD-1 for Metastasis ICC | NCT04398927 | ICC Metastatic Canc... | Folfirinox Sintilimab | 18 Years - 75 Years | Sun Yat-sen University | |
| Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis | NCT04769908 | ICC | Systemic Chemot... Lenvatinib Sintilimab | 18 Years - 75 Years | Sun Yat-sen University | |
| Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | NCT05220722 | Hepatocellular ... Intrahepatic Ch... | SD-101 Pembrolizumab Nivolumab Ipilimumab | 18 Years - 99 Years | TriSalus Life Sciences, Inc. | |
| Treatment of Advanced Intrahepatic Cholangiocarcinoma | NCT03940378 | ICC | Levamisole Hydr... Anlotinib Hydro... | 18 Years - 65 Years | The First Affiliated Hospital of Zhengzhou University | |
| Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma | NCT03633773 | Intrahepatic Ch... | MUC-1 CART cell... | 18 Years - 65 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
